13F Holdings
中文EN

CUE Cue Biopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1645460 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY401.9%
TTM net income YoY-448.5%
TTM EPS YoY-107.1%
Revenue 3-yr CAGR110.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-387.7%
Net margin-579.9%
FCF margin-143.7%
EBITDA margin-384.0%

Returns

ROE-800.4%
ROA-418.0%
ROIC (approx.)—
Asset turnover0.72x

Leverage & solvency

Liabilities / assets42.9%
Debt / equity0.00x
Current ratio3.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-314.6%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$27.47M$9.29M$5.49M$1.25M$14.94M
R&D expense$37.74M$36.30M$40.80M$38.58M$41.35M
SG&A expense$16.24M$14.59M$16.68M$16.17M$17.31M
Operating income-$26.55M-$41.50M-$52.15M-$53.23M-$43.71M
Interest expense$100,000$100,000$100,000$109,000—
Pretax income———-$53.01M-$43.67M
Income tax$500,000$0—$0$495,000
Net income-$26.60M-$40.67M-$50.73M-$53.01M-$44.16M
EBITDA-$25.59M-$41.10M-$51.59M-$52.30M-$42.45M
EPS (basic)-0.28-0.72-1.11-1.49-1.41
EPS (diluted)-0.28-0.72-1.11-1.49-1.41
Weighted avg. shares (diluted)94.73M56.33M45.75M35.65M31.29M
Banking
Net interest income-$357,000-$796,000-$1.25M-$713,000$0
Balance sheet
Cash & equivalents$27.14M$22.46M$48.51M$51.61M$64.37M
Short-term investments—$0$0$24.68M$0
Receivables$5.55M$945,000$1.70M$57,000$3.14M
Current assets$36.98M$25.14M$51.45M$77.19M$68.47M
PP&E, net$241,000$471,000$795,000$1.50M$2.11M
Total assets$42.21M$32.19M$61.53M$91.28M$83.40M
Current liabilities$13.49M$13.69M$17.08M$11.55M$12.79M
Short-term debt—$37,000$4.00M$2.00M—
Long-term debt—$0$4.20M$8.04M$0
Total debt—$37,000$8.20M$10.04M$0
Total liabilities$15.78M$14.69M$24.45M$25.60M$17.91M
Shareholders' equity$26.43M$17.50M$37.09M$65.68M$65.49M
Net debt—-$22.42M-$40.31M-$41.58M-$64.37M
Shares outstanding3.22M61.82M47.22M47.22M32.20M
Cash flow statement
Operating cash flow-$21.69M-$36.33M-$39.96M-$41.81M-$38.84M
Capital expenditure$177,000$66,000$0$171,000$913,039
Free cash flow-$21.86M-$36.40M-$39.96M-$41.98M-$39.75M
Investing cash flow$75,000$32,000$25.00M-$24.61M$9.11M
Financing cash flow$26.29M$10.24M$11.86M$53.66M$19.23M
Depreciation & amortization$958,000$397,000$556,000$922,000$1.26M
Stock-based compensation$4.74M$6.85M$8.18M$9.50M$11.52M
Share buybacks——$0$200,000$750,128

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.